SAM
REGN icon

Symphony Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Symphony Asset Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,095
Closed -$489K – 373
2017
Q3 		$489K Sell
1,095
-8
-0.7% -$3.81K 0.05% 264
2017
Q2 		$542K Sell
1,103
-54
-5% -$23.6K 0.06% 261
2017
Q1 		$448K Sell
1,157
-40
-3% -$14.8K 0.04% 299
2016
Q4 		$440K Sell
1,197
-43
-3% -$16.4K 0.04% 306
2016
Q3 		$498K Sell
1,240
-66
-5% -$26.5K 0.05% 269
2016
Q2 		$457K Sell
1,306
-67
-5% -$25.8K 0.05% 243
2016
Q1 		$495K Sell
1,373
-37
-3% -$15.2K 0.05% 251
2015
Q4 		$766K Sell
1,410
-47
-3% -$25.5K 0.08% 221
2015
Q3 		$677K Sell
1,457
-44
-3% -$23.6K 0.08% 255
2015
Q2 		$766K Buy
1,501
+50
+3% +$24.4K 0.1% 216
2015
Q1 		$655K Buy
+1,451
New +$615K 0.08% 260

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return

Symphony Asset Management's REGN Position: Q4 2017 in Review

Symphony Asset Management sold out of Regeneron Pharmaceuticals (REGN) in Q4 2017, closing a stake of 1,095 shares — an estimated $489K sold.

Symphony Asset Management first reported a position in REGN in Q1 2015 and held it in 11 quarters. The position peaked at $766K in Q4 2015. 639 funds tracked by Wall St. Rank hold REGN as of Q4 2017.

  • Symphony Asset Management reported no remaining Regeneron Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Symphony Asset Management sold 1,095 Regeneron Pharmaceuticals shares in Q4 2017, an estimated $489K.
  • Symphony Asset Management first reported a position in Regeneron Pharmaceuticals in Q1 2015 and held it in 11 quarters.
  • Symphony Asset Management's Regeneron Pharmaceuticals position peaked at $766K in Q4 2015.
  • 639 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2017.

Based on Symphony Asset Management's 13F filing for Q4 2017, filed 14 Feb 2018.